As someone that's been using Alienware monitors for ages, I think the brand has always walked a fine line between high-tech performance and aggressive sci-fi camp. When I saw the press release for ...

My equal-weighted BUY portfolio returned 23.8% from Feb 2024–Dec 2025, outperforming equal weighted RSP and two value benchmarks but trails SPY and SCHV. Portfolio underperformance versus SPY and SCHV ...

Axsome Therapeutics (AXSM) announced on Wednesday that the U.S. FDA has granted priority review for its marketing application seeking a label expansion for its depression therapy AXS-05 (Auvelity) in ...